Table 2.
Baseline characteristics of the patients treated with itolizumab versus the control patients not receiving immunomodulatory agents
| Control (n = 53) |
Itolizumab (n = 19) |
Total (N = 72) |
p (χ2) | ||||
|---|---|---|---|---|---|---|---|
| Frequency | % | frequency | % | frequency | % | ||
| Sex | |||||||
| Female | 31 | 58.5 | 11 | 57.9 | 42 | 58.3 | 0.964 |
| Male | 22 | 8.0 | 8 | 42.1 | 30 | 41.7 | |
| Age, years | |||||||
| Mean (SD) | 79.0 (10.2) | 77.3 (10.2) | 77.9 (8.6) | 0.396 | |||
| Min.; max. | 64; 100 | 65; 101 | 64; 101 | ||||
| Number of comorbidities | |||||||
| 0–1 | 20 | 37.7 | 5 | 26.3 | 25 | 34.7 | 0.362 |
| 2 or more | 33 | 62.3 | 14 | 73.7 | 47 | 65.3 | |
| Arterial hypertension | 39 | 73.6 | 14 | 73.7 | 53 | 73.6 | 0.993 |
| Diabetes mellitus | 24 | 45.3 | 6 | 31.6 | 30 | 41.7 | 0.293 |
| Ischemic heart disease | 20 | 37.7 | 8 | 42.1 | 28 | 38.9 | 0.738 |
| COPD | 7 | 13.2 | 5 | 26.3 | 12 | 16.7 | 0.280 |
| Asthma | 3 | 5.7 | 1 | 5.3 | 4 | 5.6 | 1.000 |
| Cancer | 5 | 9.4 | 0 | 0.0 | 5 | 6.9 | 0.316 |
| Obesity | 2 | 3.8 | 1 | 5.3 | 3 | 4.2 | 1.000 |
| Malnutrition | 0 | 0.0 | 10 | 52.6 | 10 | 13.9 | 0.000 |
| Chronic kidney disease | 8 | 15.1 | 0 | 0.0 | 8 | 11.1 | 0.100 |
Bold type denotes significance. COPD, chronic obstructive pulmonary disease.